SCHEMBL6502402

SCHEMBL6502402

COc1ccc(-c2nc3cc(Cl)c(Cl)cc3[nH]2)cc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 3/20 0.55
ALOX5 P09917 1/20 0.52
EPHX2 P34913 1/20 0.52
HPGD P15428 6/20 0.50
ALDH1A1 P00352 5/20 0.50
NPC1 O15118 5/20 0.50
KDM4E B2RXH2 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
MEN1 O00255 4/20 0.50
TP53 P04637 4/20 0.50
KMT2A Q03164 4/20 0.50
RAB9A P51151 4/20 0.50
POLB P06746 3/20 0.50
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
GAA P10253 2/20 0.50
USP2 O75604 1/20 0.50
THRB P10828 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502848 0.82 RHEB (0.59) RHEBALOX5EPHX2AMY1ACHEK2
SCHEMBL2349584 0.81 SMN1; SMN2 (0.68) ALOX5EPHX2HPGDALDH1A1NPC1
SCHEMBL6281866 0.80 ALDH1A1 (0.54) ALOX5EPHX2HPGDALDH1A1NPC1
SCHEMBL21642885 0.80 ALOX5 (0.56) RHEBALOX5EPHX2HPGDALDH1A1
SCHEMBL4716703 0.79 MAPT (0.53) RHEBALOX5EPHX2HPGDALDH1A1
SCHEMBL6282773 0.78 ALDH1A1 (0.77) ALOX5EPHX2HPGDALDH1A1NPC1
SCHEMBL6324494 0.77 RHEB (0.69) RHEBHPGDALDH1A1NPC1KDM4E
SCHEMBL11603170 0.76 ALOX5 (0.74) ALOX5EPHX2HPGDALDH1A1KDM4E
SCHEMBL7089024 0.76 CYP1A1 (0.43) HPGDALDH1A1NPC1KDM4ESMN1; SMN2
SCHEMBL6494925 0.76 CYP1A1 (0.43) HPGDALDH1A1NPC1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US claimed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP claimed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6858739-B2 Indole and benzimidazole 15-lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-22 US disclosed
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US disclosed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP disclosed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors ALOX15, ALOX5, ALOX12 RHEB 3812/4885ALOX5 2/4885EPHX2 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.